Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.

Published

Journal Article

Cytotoxic chemotherapy that induces lymphopenia is predicted to ablate the benefits of active antitumor immunization. Temozolomide is an effective chemotherapeutic agent for patients with glioblastoma multiforme, but it induces significant lymphopenia. Although there is monthly fluctuation of the white blood cell count, specifically the CD4 and CD8 counts, there was no cumulative decline in the patient described in this case report. Depriving patients of this agent, in order to treat with immunotherapy, is controversial. Despite conventional dogma, we demonstrated that chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy. In fact, the temozolomide-induced lymphopenia may prove to be synergistic with a peptide vaccine secondary to inhibition of regulatory T cells or their delayed recovery.

Full Text

Duke Authors

Cited Authors

  • Heimberger, AB; Sun, W; Hussain, SF; Dey, M; Crutcher, L; Aldape, K; Gilbert, M; Hassenbusch, SJ; Sawaya, R; Schmittling, B; Archer, GE; Mitchell, DA; Bigner, DD; Sampson, JH

Published Date

  • February 2008

Published In

Volume / Issue

  • 10 / 1

Start / End Page

  • 98 - 103

PubMed ID

  • 18079360

Pubmed Central ID

  • 18079360

International Standard Serial Number (ISSN)

  • 1522-8517

Digital Object Identifier (DOI)

  • 10.1215/15228517-2007-046

Language

  • eng

Conference Location

  • England